Guo XX, et al. - In this meta-analysis of published randomized controlled trials, researchers assessed the efficacy and safety of olaparib in cancer patients, with a focus on overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade 3/4 adverse events. They analyzed eight trials involving 1,957 patients. In the pooled analysis, olaparib treatment vs therapy not containing olaparib was shown to result in significant improvements in PFS, OS, and ORR. Sensitivity analysis further corroborated this association. In patients with BRCA mutation, a significant survival benefit was seen with olaparib treatment. However, treatment with olaparib was found to be related to a significant increase in risk of severe anemia.